Latest Health Care Reform Draft Details Government Responsibilities
This article was originally published in PharmAsia News
Executive Summary
The new draft of China's health care reform plan was released on Oct. 14 to solicit public opinion for the second time. It systematically addresses the reform's direction, objectives, principles and major measures. Zhu Chang-Hao, vice-chairman of the China Association of Pharmaceutical Commerce, sees the biggest highlight as the government's clear definition of responsibilities for the first time, realistically sharing the investment load between the central and local governments at all levels. However, some parts are not clearly spelled out: for instance, the plan does not indicate how to dissociate profits between health care services and medicines, or how to balance the interests among national taxes, health care institutions, physicians, pharmaceutical companies and patients. Analysts note the reform will help to strengthen domestic growth and economic stability. (Click here for more - Chinese Language)
You may also be interested in...
China Set To Launch Sweeping Health System Reforms, Aimed In Part At Reversing Stratified Access To Medicine, Hospitals, Insurance
BEIJING - China's central government is set to launch sweeping reforms of the country's health system, with the ultimate goal of providing universal health care by the year 2020
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.